Subtype
Thyroid Gland Neoplasm
CI-CAN-00001600Explore in graph →
Non-malignant189 active trials10 approved drugs63 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001600Explore in graph →
Clinical trials
891 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07459283 | The Safety, Dosimetry and Efficacy of 177Lu-INN805 in Patients With Malignant Solid Tumors | recruiting | Early Phase 1 | 10 | FindCure Biosciences (ZhongShan) Co., Ltd.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06639191 | [177Lu]Lu-AKIR001 First-in-human Study(AKIR001) | recruiting | Early Phase 1 | 15 | Karolinska University HospitalOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT06898437 | Study of 177Lu-LNC1004 Injection in FAP-positive Radioiodine-refractory Differentiated Thyroid Cancer | recruiting | Early Phase 1 | 20 | Peking Union Medical College HospitalOTHER | 1 | Apr 15, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Sep 4, 2026source: clinicaltrials